Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase EARLY_PHASE1 × Withdrawn × Chalazion × Clear all

Phase

Phase EARLY_PHASE1 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Breast Neoplasms 15 Pancreatic Neoplasms 10 Neoplasms 8 Prostatic Neoplasms 7 Ovarian Neoplasms 5 Head and Neck Neoplasms 5 Glioma 5 Carcinoma, Non-Small-Cell Lung 5 Triple Negative Breast Neoplasms 4 Squamous Cell Carcinoma of Head and Neck 4 Polycystic Ovary Syndrome 4 Glioblastoma 4 Colonic Neoplasms 4 Obesity 3 Neoplasm Metastasis 3 Multiple Myeloma 3 Melanoma 3 Lung Neoplasms 3 Carcinoma, Intraductal, Noninfiltrating 3 Brain Neoplasms 3 Sarcoma 2 Pain, Postoperative 2 Lymphoma 2 Fallopian Tube Neoplasms 2 Esophageal Neoplasms 2 Depression 2 Warts 1 Uveal Melanoma 1 Uterine Cervical Dysplasia 1 Urinary Bladder Neoplasms 1

Interventions

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT01763437 2017-01-12

TET

The Cleveland Clinic

Phase EARLY_PHASE1 Withdrawn

Meibomian Gland Dysfunction, Rosacea, Chalazion

Data powered by HemOnc (CC BY 4.0) Colophon ⚡